PRELUDE THERAPEUTICS INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PRELUDE THERAPEUTICS INC (PRLD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.69 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $12.95, a 51.29% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.56, a 45.34% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $15.66, a 20.47% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $19.69, a 10.25% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $6.11, a 32.78% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $9.09, a 27.74% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $12.58, a 29.48% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $17.84, a 9.85% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.69 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $12.95 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $6.11 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $6.81 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $7.22 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $8.56 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $9.09 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $12.18 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $12.49 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $15.66 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $12.58 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $15.59 10-Q · filed 2023-11-01 | |||
| 2023-06-30 | $17.72 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $19.69 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $17.84 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $18.10 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $18.06 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $17.86 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $19.79 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $21.68 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $43.36 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $7.94 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $1.37 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $1.37 10-Q · filed 2020-11-10 | |||
| 2019-12-31 | $1.02 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |